Kornimate/medical-research-clean huggingface dataset:
effects of ayres sensory integration therapy versus conservative treatment in autism spectrum

Conditions: Autism Spectrum Disorder

Summary: effects of ayres sensory integration therapy versus conservative treatment in autism spectrum

"this study named effects of ayres sensory integration therapy versus conservative treatment in autism spectrum is a randomized clinical trail study.there is no evidence-based intervention protocol to treat sensory integration dysfunction in autism spectrum. this study may help finding best therapeutic treatment approach for sensory integration dysfunction results in repetitive behavior and impairments in functionality in autism spectrum.this study helps * to evaluate best intervention plan for sensory integration dysfunction, ayres sensory integration therapy versus conservative treatment in autism spectrum. * to determine how many patients will be having what type of sensory integration dysfunction that come with autism spectrum leading to certain level of functional restrictions in activity of daily livings (adls). * which type of sensory integration dysfunction having greater functional impairment and need to be focused more for intervention? * to make better individualized rehabilitation treatment plan being an occupational therapist."

Eligibility criteria:
inclusion criteria: * diagnosed cases of autism age range from 2 year to 8 years. * all patients will be assed using sensory profile by winnie dunn. * all the patients fulfilling the above-mentioned inclusion criteria will be assessed and evaluated by occupational therapist for sensory integration dysfunction. exclusion criteria: * all other patients not having diagnosed as autism spectrum criteria are excluded. * all patients with sensory processing disorder assessed by using sensory profile.
the impact of picture narrative format on print lung screening communication outcomes

Conditions: Cancer Screening

Summary: the purpose of this study is to test whether a picture narrative format is more successful, than text with pictures or text alone, in communicating lung screening information (primarily defined by positive attitudes towards the design and increase in knowledge) to people likely to be invited to lung screening where available.

population screening is key to detecting lung cancer early at a more treatable stage. uptake of screening should be equitable (i.e., screening benefits all eligible members of the population and does not contribute further to health disparities) and informed (i.e., participants have been involved in the decision to take part and their decision aligns with their values and circumstances). print decision support materials are the primary mechanism for encouraging engagement with cancer screening and supporting decision making. it is essential that we identify print communication techniques that are effective in informing invitees about lung screening. the intervention, picture narrative information about lung screening, was previously developed through codesign and prototype testing with people likely to be eligible for lung screening (50 to 75 years old, past or current heavy smokers). participants will be randomised to one of three groups: picture narrative format, text with pictures (control 1) or, text-only (control 2). this study will assess whether presenting lung screening information in a picture narrative format can improve lung cancer screening knowledge, eligibility self-assessment and attitudes. it will also assess whether perceptions of the information designs can explain any impact of the intervention on these outcomes and whether there are differences across socioeconomic groups.

Eligibility criteria:
inclusion criteria: * living in glasgow * willing and able to respond unaided to invitation to participate in the trial and give informed consent. * aged between 49 and 75 years exclusion criteria:

Keywords: health communication lung cancer screening messages comprehension visual narrative comics
use of warm compresses during the second stage and the risk of perineal tears

Conditions: Perineum; Tear

Summary: there is a controversy regarding whether warm compresses influence the rate of intact perineum after a vaginal delivery. according to a meta-analysis published in 2019 that included 7 randomized prospective trials, approximately 2103 participants, the use of warm compresses during the second stage of labor increased the chance of an intact perineum rr=1.46, decreased the chance of a third degree tear rr=0.38 and grade four tear rr=0.11. the limitations noted in this meta-analysis include non-uniformity in the methods of the studies included in the meta-analysis in terms of the number of participants, the duration of use of the compresses, and the temperature of the compresses. in summary, it is reported that there is a need for more randomized studies. since there is a need for more randomized studies in the field, the study's goal is to conduct a randomized study that will compare the use of warm compresses in the second stage of labor against a standard care control group (almond oil) - in terms of perineal tear that will require suturing.

various techniques have been developed to prevent the development of perineal tears. as reported in the literature, active protection of the perineum during the second stage of labor can reduce the rate of tears. these include massage of the perineum, hands-on technique, use of gel, and warm compresses. according to a cochrane review that examined the use of warm compresses published in 2017, there is no difference in terms of the rate of events of an intact perineum, perineal trauma that requires suturing, but in a subanalysis it showed that there is a decrease in the rate of advanced tears, involving the anal sphincter and the rectal mucosa (grade three and four). according to a meta-analysis published in 2019 that included 7 randomized prospective trials, approximately 2103 participants, the use of warm compresses during the second stage of labor increased the chance of an intact perineum rr=1.46, decreased the chance of a third degree tear rr=0.38 and grade four tear rr=0.11. the limitations noted in this meta-analysis include non-uniformity in the methods of the studies included in the meta-analysis in terms of the number of participants, the duration of use of the compresses, and the temperature of the compresses. in summary, it is reported that there is a need for more randomized studies. since there is a need for more randomized studies in the field, the study's goal is to conduct a randomized study that will compare the use of warm compresses in the second stage of labor against a standard care control group (almond oil) - in terms of perineal tear that will require suturing.

Eligibility criteria:
inclusion criteria: * term pregnancy * singleton pregnancy * vertex presentation exclusion criteria: * women with a history of third degree perineal tear in the past * intrauterine fetal death * crohn disease with perineal involvement

Keywords: perineal tear warm compresses intact perineum almond oil
effect of atorvastatin administration before primary percutaneous coronary intervention

Conditions: Angioplasty, Transluminal, Percutaneous Coronary

Summary: the purpose of this study to determine whether statin pretreatment decrease myocardial infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.


Eligibility criteria:
inclusion criteria: * presence of chest pain for more than 30 minutes but less than 12 hours after symptom onset * st segment elevation more than 1 mm in two or more contiguous leads or presumably a new onset left bundle branch blockage exclusion criteria: * cardiogenic shock * history of myocardial infarction * chronic liver disease * previous or current statin use

Keywords: myocardial infarct size atorvastatin spect hydroxymethylglutaryl-coa reductase inhibitors
virtual reality training on balance, postural stability, mobility and quality of life in obese patients

Conditions: Obesity/Therapy; Obesity (Body Mass Index &gt;30 kg/m2)

Summary: the aim of this study will be to evaluate the effect of adding virtual reality training to balance exercise program on improving balance, postural stability, mobility and quality of life in obese patients.


Eligibility criteria:
inclusion criteria: 1. participants with 20 to 40 years old, 2. participants with bmi of 30 to 39.9 kg/m2 3. absence of neurological disorders i.e.: stroke, ataxia, or parkinsonism. exclusion criteria: 1. participants with vestibular or vision problem. 2. participants with diabetes mellitus or cardiorespiratory disorders. 3. participants with severe obesity bmi ≥40. 4. participants at regular physical therapy exercise training program at the last 3 months. 5. participants who are unable to follow instructions due to personal or cognitive problems.

Keywords: virtual reality training balance postural stability quality of life obese
the effect of muscular strength training in patients with drug addiction

Conditions: Substance-related Disorders

Summary: physical health does not have a high priority in today's treatment of patients with substance use disorder (sud). sud patients have a poor physical health not only due to injuries related to the substance abuse, but also because of the addiction-related lifestyle. there are few studies today that provide information about sud patient's physical health, and especially there is little information about their muscular strength. one of the project's aims is to measure muscular strength in sud patients who are being treated for their addiction, and see if they have decreased neuromuscular function. if so, we will investigate the effect of maximal strength training on neuromuscular function in these patients.


Eligibility criteria:
inclusion criteria: * being treated for drug abuse * not using drugs during intervention period exclusion criteria: * participated in strength training in previous 6 months * cardiovascular disease * any other disease that impedes to finish tests * not showing up for testing sessions * carried out less than 85% of planned exercise sessions

Keywords: rehabilitation strength training muscle strength physical fitness
neoadjuvant gtx with chemoradiation for pancreatic cancer (stage ii/iii)

Conditions: Pancreatic Cancer Stage II; Pancreatic Cancer Stage III

Summary: this study is for patients with locally advanced pancreatic cancer (cancer that involves the local blood vessels so it cannot be removed without cutting major blood vessels) that cannot be treated with surgery. the purpose of this study is to assess the safety and benefit of 6 three week cycles of chemotherapy treatment consisting of gemcitabine, capecitabine and docetaxel (also called 'gtx'). the patients fall into two groups. group i are those with only venous involvement. group ii patients have arterial involvement and may also have venous involvement. if there is arterial involvement, gtx will be followed by 5 and 1/2 weeks of radiation therapy with gemcitabine and capecitabine. after the chemotherapy and radiation treatment, participants may be able to have surgery to remove any remaining pancreatic cancer.


Eligibility criteria:
inclusion criteria: * histologically confirmed adenocarcinoma of the pancreas (when possible the tissue should be evaluated for k-ras mutation and the patient evaluated for brca and p16 mutations.) * locally advanced disease determined by endoscopic ultrasound, ct scan (chest/abdomen/pelvis with contrast), mri scan (of abdomen with gadolinium) or pet scan. * no evidence of metastatic disease by ct scan (chest/abdomen/pelvis with contrast), mri scan (of abdomen with gadolinium) or pet scan. * unresectable tumor. (this reflects those patients whose tumors abut, invade or surround a major vessel, either venous or arterial or both) * no prior chemotherapy or radiation therapy. * ineligible for other high priority national or institutional studies. * negative serum or urine β-hcg within 1 week of starting treatment for non-pregnant, non-menopausal females. * must not have other underlying medical conditions that would make them ineligible for surgery, radiation therapy, or chemotherapy. * complete blood count and complete metabolic profile: absolute neutrophil count \> 1,500 μl white blood count \> 3,000/μl platelet count \> 100,000/μl bun \ 8.0 g/dl serum albumin \> 3 mg/dl total bilirubin \< 3.0 mg/dl sgot, sgpt, alkaline phosphatase \< 2.5 x uln * informed consent: each patient must be completely aware of the nature of his/her disease process and must willingly give consent after being informed of the nature of this therapy, alternatives, potential benefits, side-effects, risks, and discomforts.
ocular surface disease and iop monitoring with travoprost without conservatives

Conditions: Glaucoma; Glaucoma; Drugs; Ocular Surface Disease

Summary: primary objective of this study is to study the efficacy of travoprost without preservatives in the treatment of glaucoma patients and to monitor the ocular surface.

this is a prospective study including patients visiting the outpatient glaucoma clinic of the university general hospital of alexandroupolis for their standard evaluation. study population is already under treatment with a travoprost preparation without preservatives. they will be fully informed about the procedure and the purpose of the study and a written consent will be obtained. for every patient included in the study intraocular pressure will be measured using a goldman applanation tonometer, according to the standard way of practice at our clinic. also, tear break-up-time (but), conjunctival hyperemia grading and schirmer testing will be used to assess the ocular surface state. visual field tests and oct rnfl measurements will also be obtained. the above measurements will be repeated 6 months after the initial examination.

Eligibility criteria:
inclusion criteria: * patients with glaucoma treated with travoprost without preservatives. exclusion criteria: * co-administration of another anti-glaucoma preparation with or without preservatives, sjogren's syndrome, poor eyelid occlusion of any etiology.

Keywords: glaucoma travoprost prostaglandin without preservatives
4d-150 in patients with neovascular (wet) age-related macular degeneration

Conditions: Neovascular (Wet) Age-Related Macular Degeneration

Summary: phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet amd undergoing active anti-vegf treatment

this phase 1/2 trial is a prospective, multicenter, phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet amd undergoing active anti-vegf treatment who have demonstrated a clinical response consistent with anti-vegf activity. the trial consists of dose escalation, dose expansion, steroid optimization and population extension cohorts. after receiving one time administration of 4d-150 by intravitreal injection, subjects will undergo assessments at monthly intervals for 24 months to assess safety and efficacy outcomes. only subjects that received 4d-150 will then enter a long-term follow-up (ltfu) period to assess long-term safety of 4d-150 gene therapy and duration of clinical activity through year 5 (60 months).

Eligibility criteria:
inclusion criteria: * ≥50 years of age * diagnosed with macular cnv secondary to amd * bcva etdrs snellen equivalent for dose escalation between \~20/32 and \~20/320, or for dose expansion and population extension between \~20/25 and\~20/200, for steroid optimization between \~20/25 and \~20/640 * currently receiving anti-vegf treatment in the study eye and has demonstrated a clinical response consistent with anti-vegf activity within 12 months prior to screening exclusion criteria: * any condition preventing visual acuity improvement in the study eye * prior treatment with photodynamic therapy or retinal laser in the study eye * history of uveitis in either eye * any other pre-existing eye conditions or surgical complications that would preclude participation in an interventional clinical trial or interfere with the interpretation of study endpoints

Keywords: age-related macular degeneration amd exudative amd exudative age-related macular degeneration neovascular amd neovascular age-related macular degeneration wet age-related macular degeneration wet macular degeneration wet amd wamd retinal gene therapy intravitreal gene therapy genetic medicine ocular gene therapy
reducing cardiovascular risk in adults with serious mental illness

Conditions: Chronic Disease; Mental Disorder; Health Behavior; Bipolar Disorder; Schizophrenia

Summary: this purpose of this study is to adapt, implement and test the ability of a sophisticated point-of-care electronic health record-based clinical decision support that identifies and prioritizes all available evidence-based treatment options to reduce cardiovascular risk in patients with serious mental illness.

this study adapted a point-of-care electronic health record-based clinical decision support system (the cardiovascular wizard) to help primary care providers identify, provide appropriate care for, and control cardiovascular risk factors for patients with serious mental illness (bipolar disorder, schizophrenia, schizo-affective disorder). the cardiovascular wizard is designed to educate primary care providers about the increased risk of cardiovascular disease and mortality in people with serious mental illness, identify elevated cardiovascular risk factors in patients with serious mental illness, identify elevated cardiovascular risk factors in patients with serious mental illness, prioritize these cardiovascular risk based on how much improvement in cardiovascular risk a patient would experience if the cardiovascular risk factor was adequately addressed, recommend specific medications and other interventions to decrease each elevated cardiovascular risk factor, and provide this information in an easy-to-understand format for both patients with serious mental illness and their primary care providers. the cardiovascular wizard was printed in intervention clinics and (i) compiled lab data (most recent glycated hemoglobin, systolic blood pressure and low-density lipoprotein levels), body mass index, smoking status, and aspirin use, (ii) calculated a modifiable 10 year cardiovascular risk for stroke or heart attack using the american college of cardiology/american heart association 10-year atherosclerotic cardiovascular disease risk equation, (iii) prioritized clinical domains based on the absolute risk reduction for each component, (iv) compiled information related to liver and renal function, creatinine kinase level, and previous diagnoses (congestive heart failure, cardiovascular disease, diabetes mellitus, and (v) provided recommendations for intensification of therapy for glycated hemoglobin, systolic blood pressure, and/or low-density lipoproteins if not at goal. recommendations were based on evidence-based protocols including joint national committee, american diabetes association, and the institute for clinical systems improvement.

Eligibility criteria:
inclusion criteria: * serious mental illness diagnosis * age 18-75 * index visit during the enrollment period * first primary care visit where patient was not at goal for at least one of the six cardiovascular risk factor areas, and patient was not pregnant * one or more post-index visits during the intervention period exclusion criteria: * no serious mental illness diagnosis * under age 18 or over age 75 * in hospice or nursing home * at goal for all cardiovascular risk 6 areas * on research exclusion list
prescription patterns, resource utilization & costs - add-on therapy with anti dipeptidyl peptidase-ivs vs rosiglitazone

Conditions: Diabetes Mellitus, Type 2

Summary: this retrospective database study analyzed resource utilization and costs associated with sitagliptin (stg) in comparison with rosiglitazone (rsg) added to metformin (met) monotherapy among adults with a diagnosis of diabetes who were continuously enrolled in a large us healthcare plan.


Eligibility criteria:
inclusion criteria: * continuously enrolled in the health insurance plan to ensure complete claims coverage * at least 1 claim with a diagnosis of diabetes (icd-9 250.xx) * aged 18 years or older at the index date * at least 6 months of baseline period prior to the index date * at least 1 claim for met during the baseline period * at least 180 days of continuous therapy with rsg+met or stg+met after the index date exclusion criteria: * at least 1 claim for insulin or sulfonylurea in the baseline period * at least 1 claim with a diagnosis of congestive heart failure in the baseline period

Keywords: retrospective type 2 diabetes cost analysis rosiglitazone sitagliptin
study of administration of antithrombin in patients with low plasmatic levels of antithrombin after cardiac surgery

Conditions: Aortic Valve Insufficiency; Aortic Valve Stenosis; Mitral Valve Insufficiency; Mitral Valve Stenosis; Acute Coronary Syndrome

Summary: general and specific objectives of the search: evaluate the effects of the administration of antithrombin iii (atiii) on the activation of the coagulation system and of the fibrinolysis, platelet function, inflammatory response and markers of organ damage in patients undergoing cardiac surgery by cardiopulmonary bypass (cpb) with low plasma levels of post-operative antithrombin (at).


Eligibility criteria:
inclusion criteria: * all patients were candidates for cardiac surgery intervention in extracorporeal circulation exclusion criteria: * positive history for allergic reactions to at iii * cardiac surgery "off-pump" * administration of at during surgery or within 48 h * treatment with drugs and non-steroidal steroids within 48 h prior * disorders of coagulation * platelets \<30,000 * pre-existing irc in dialysis treatment * severe liver failure * enlistment in another trial in the last 30 days * hypothermia * emergency * reopening * length of cec\> 180 minutes * subjects incapable of giving legal consent